United States Uterine Fibroids Treatment Devices Market to Grow with a CAGR of 9.23% through 2030
Growing
awareness about women’s reproductive health and advancements in fibroid
treatment technologies, is expected to drive the United States Uterine
Fibroids Treatment Devices Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “United States Uterine Fibroids Treatment Devices
Market – By Region and Competition, Forecast & Opportunities, 2030F”,
the United States Uterine Fibroids Treatment Devices Market was valued at USD 2.83 Billion in
2024 and is expected to reach USD 4.81 Billion by 2030 with a CAGR of 9.23%. The United States Uterine
Fibroids Treatment Devices Market is progressing as the focus on
patient-centric care intensifies across the healthcare landscape. Personalized
treatment planning, driven by better understanding of fibroid pathology and
symptom variability, is pushing the demand for targeted device-based therapies.
Patients are increasingly seeking alternatives that offer minimal disruption to
daily life, fueling innovation in device platforms that offer reduced procedure
time and enhanced precision. As medical technology companies continue to design
more ergonomic and user-friendly equipment for fibroid management, hospitals
and ambulatory surgical centers are expanding their capabilities to include a
wider array of treatment options beyond conventional surgery.
Emerging
trends in the market include the integration of robotics and artificial
intelligence into surgical platforms for gynecological procedures. These
technologies are enabling higher accuracy and consistency in fibroid removal
while reducing the learning curve for new practitioners. The expansion of
value-based care models is also influencing device selection, with hospitals
favoring tools that provide better patient outcomes and long-term cost savings.
Increasing clinical trials evaluating the safety and efficacy of novel
energy-based devices are further encouraging providers to consider
device-assisted options in standard treatment protocols. The market is also
seeing increased partnerships between medtech companies and healthcare systems
aimed at improving product accessibility and post-operative care.
Growth
opportunities in the market are expected to emerge from the untapped potential
in outpatient and office-based treatment settings. As reimbursement models
evolve to support these cost-effective approaches, medical practices are
beginning to invest in compact, portable treatment devices suitable for
in-office use. There is a rising opportunity to cater to the growing population
of women delaying childbirth, who are more likely to seek fertility-preserving
solutions. Expanding direct-to-consumer education campaigns, combined with
digital health platforms for symptom tracking and virtual consultations, can
further broaden patient outreach. Companies that can effectively integrate
advanced technologies with patient-friendly treatment experiences are well-positioned
to capitalize on this expanding market segment.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "United States Uterine Fibroids Treatment Devices Market”
The United
States Uterine Fibroids Treatment Devices Market is segmented into technology, mode
of treatment, end user, regional distribution, and company.
Based on the Mode
of Treatment, Non-invasive Treatment emerged as the fastest growing segment in
the United States Uterine Fibroids Treatment Devices Market during the forecast
period. This is driven by increasing patient demand for procedures that avoid
surgery, reduce recovery times, and preserve the uterus. Non-invasive methods,
such as high-intensity focused ultrasound (HIFU), uterine artery embolization
(UAE), and magnetic resonance-guided focused ultrasound (MRgFUS), have gained
significant popularity due to their ability to target fibroids without the need
for incisions or prolonged hospital stays. These treatments are especially
attractive to women who wish to avoid the risks and complications associated
with traditional surgery, such as hysterectomy.
Based
on the Region, West emerged as the fastest growing region in the United
States Uterine Fibroids Treatment Devices Market during the forecast period. This is driven by several key
factors. The region is home to some of the nation’s leading healthcare
institutions and medical centers, particularly in states like California and
Washington, where advancements in medical technologies and treatment options
are widely adopted. These areas are also known for their progressive approach
to women’s health, with an increasing emphasis on minimally invasive and
uterus-preserving procedures for uterine fibroids. The West also benefits from
a high concentration of specialized healthcare providers, including
gynecologists and interventional radiologists, who are skilled in the use of
advanced fibroid treatment devices. With a population that is more informed and
proactive about healthcare choices, women in this region are more likely to
seek alternative treatments such as uterine artery embolization (UAE),
high-intensity focused ultrasound (HIFU), and other non-invasive procedures.
Additionally, the West sees a higher rate of private healthcare insurance
coverage, which makes these advanced treatment options more accessible.
Major
companies operating in United States Uterine Fibroids Treatment Devices Market
are:
- Minerva
Surgical, Inc.
- Stryker
Corporation
- Hologic,
Inc.
- Gynesonics
Inc.
- Medtronic
Plc.
- Boston
Scientific Corporation
- Pfizer
Inc.
- Abbvie
Inc.
- CooperSurgical
Inc.
- Olympus
Corporation
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The United States Uterine Fibroids
Treatment Devices Market is expanding due to the increasing availability and
adoption of insurance coverage for advanced fibroid treatments. As insurance
providers continue to expand their coverage to include non-invasive and
minimally invasive procedures, more women are gaining access to advanced
treatment options. This financial support reduces the out-of-pocket expenses
for patients, making high-quality uterine fibroid treatments more affordable
and accessible. The growing number of insurance plans that cover innovative
treatments such as uterine artery embolization and high-intensity focused
ultrasound is encouraging both patients and healthcare providers to opt for
these alternatives over traditional surgeries.,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“United States Uterine
Fibroids Treatment Devices Market By Technology (Surgical Techniques, Laparoscopic
Techniques, Ablation Techniques, Embolization Techniques), By Mode of Treatment
(Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment), By
End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By
Region and Competition, Forecast & Opportunities, 2020-2030F”,
has evaluated the future growth potential of United States Uterine Fibroids
Treatment Devices Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in United States Uterine
Fibroids Treatment Devices Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com